Lv3
370 积分 2025-03-04 加入
Preventing sepsis development in complicated urinary tract infections
1个月前
已完结
Urinary Tract Infection Prevention and Treatment
1个月前
已完结
Distinct clinical features of urothelial carcinoma with low-expressing human epidermal growth factor receptor 2 status
2个月前
已关闭
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2个月前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
5个月前
已完结
Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study
5个月前
已关闭
Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma
5个月前
已完结
Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab
5个月前
已完结
Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis
5个月前
已完结
Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial
6个月前
已完结
皖公网安备34019202002308
